FY2025 EPS Estimates for Surmodics Increased by Analyst

Surmodics, Inc. (NASDAQ:SRDX) – Research analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for Surmodics in a research report issued on Monday, November 25th. Zacks Research analyst D. Dey now forecasts that the company will earn $0.14 per share for the year, up from their previous forecast of $0.13. The consensus estimate for Surmodics’ current full-year earnings is $0.17 per share. Zacks Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.21 EPS, Q2 2026 earnings at $0.13 EPS, Q3 2026 earnings at $0.20 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.78 EPS and FY2027 earnings at $0.81 EPS.

Other research analysts have also issued research reports about the company. StockNews.com assumed coverage on Surmodics in a report on Saturday. They set a “hold” rating for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research note on Thursday, November 7th. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, Surmodics has an average rating of “Hold” and a consensus price target of $50.00.

Surmodics Stock Up 0.1 %

Shares of SRDX opened at $39.58 on Wednesday. Surmodics has a twelve month low of $25.17 and a twelve month high of $42.44. The company has a current ratio of 3.96, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25. The business’s 50-day moving average price is $38.50 and its 200-day moving average price is $39.53.

Surmodics (NASDAQ:SRDX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.14. Surmodics had a negative return on equity of 3.79% and a negative net margin of 9.15%. The firm had revenue of $33.23 million for the quarter, compared to analysts’ expectations of $30.69 million.

Hedge Funds Weigh In On Surmodics

A number of institutional investors have recently added to or reduced their stakes in SRDX. Vanguard Group Inc. raised its holdings in Surmodics by 0.7% in the first quarter. Vanguard Group Inc. now owns 865,214 shares of the company’s stock worth $25,385,000 after purchasing an additional 5,927 shares in the last quarter. Lazard Asset Management LLC grew its stake in shares of Surmodics by 13.4% in the first quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock worth $166,000 after acquiring an additional 673 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Surmodics by 4,722.3% in the second quarter. Nisa Investment Advisors LLC now owns 68,429 shares of the company’s stock worth $2,877,000 after acquiring an additional 67,010 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Surmodics by 16.3% in the second quarter. Bank of New York Mellon Corp now owns 58,610 shares of the company’s stock worth $2,464,000 after acquiring an additional 8,220 shares during the last quarter. Finally, Bailard Inc. purchased a new stake in shares of Surmodics in the second quarter worth $257,000. Institutional investors own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).